title: Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
abstract: Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human immune system. The recent development of new antibodies against immune check points may help to overcome the immune silencing induced by human tumors. Some of these antibodies have already been approved for treatment of various solid tumor entities. Interestingly, targeting antibodies may be combined with standard chemotherapy or radiation protocols. Furthermore, recent evidence indicates that intratumoral or intravenous injections of replicative oncolytic viruses such as herpes simplex-, pox-, parvo-, or adenoviruses may also reactivate the human immune system. By generating tumor cell lysates in situ, oncolytic viruses overcome cellular tumor resistance mechanisms and induce immunogenic tumor cell death resulting in the recognition of newly released tumor antigens. This is in particular the case of the oncolytic parvovirus H-1 (H-1PV), which is able to kill human tumor cells and stimulate an anti-tumor immune response through increased presentation of tumor-associated antigens, maturation of dendritic cells, and release of pro-inflammatory cytokines. Current research and clinical studies aim to assess the potential of oncolytic virotherapy and its combination with immunotherapeutic agents or conventional treatments to further induce effective antitumoral immune responses.
authors.affiliation: 1st Department of Internal Medicine, University Medical Center of the Johannes Gutenberg, University of Mainz , Mainz , Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Moehler
authors.affiliation: 1st Department of Internal Medicine, University Medical Center of the Johannes Gutenberg, University of Mainz , Mainz , Germany.
authors.forename: Katrin
authors.initials: K
authors.lastname: Goepfert
authors.affiliation: 1st Department of Internal Medicine, University Medical Center of the Johannes Gutenberg, University of Mainz , Mainz , Germany.
authors.forename: Bernd
authors.initials: B
authors.lastname: Heinrich
authors.affiliation: Jennerex Biotherapeutics, Inc. , San Francisco, CA , USA.
authors.forename: Caroline J
authors.initials: CJ
authors.lastname: Breitbach
authors.affiliation: 1st Department of Internal Medicine, University Medical Center of the Johannes Gutenberg, University of Mainz , Mainz , Germany.
authors.forename: Maike
authors.initials: M
authors.lastname: Delic
authors.affiliation: 1st Department of Internal Medicine, University Medical Center of the Johannes Gutenberg, University of Mainz , Mainz , Germany.
authors.forename: Peter Robert
authors.initials: PR
authors.lastname: Galle
authors.affiliation: Division of Tumor Virology, German Cancer Research Center (DKFZ) , Heidelberg , Germany.
authors.forename: Jean
authors.initials: J
authors.lastname: Rommelaere
keywords: CTLA-4; H-1PV; JX-594; T-VEC; autonomous parvovirus; dendritic cells; immunotherapy; talimogene laherparepvec